The percentage of measured prostate-specific antigen (PSA) existing in the free form (free:total PSA ratio) is useful in assessing the risk of prostate cancer in patients with borderline or moderately increased total PSA (4.0-10.0 ng/mL) and has been used to help select men who should have follow-up prostate biopsy
Most prostate cancers are slow growing, so the utility of prostate cancer screening is marginal in most men with a life expectancy of <10 years.
Electrochemiluminescent Immunoassay (ECLIA)
PSA Total and Free, S
PSA (Prostate-Specific Antigen)
PSA Free/Total Ratio
PSA Total and Free